Author

Michael Sangi

Institution: Gilead Sciences (United States)

Observed institution: Gilead Sciences (United States)

OpenAlex ID: A5028902162

Discovery of an Oral Respiratory Syncytial Virus (RSV) Fusion Inhibitor (GS-5806) and Clinical Proof of Concept in a Human RSV Challenge Study

2015 · Richard L. Mackman, Michael Sangi, et al. · Journal of Medicinal Chemistry · 130

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®

2019 · James G. Taylor, Sheila Zipfel, et al. · Bioorganic & Medicinal Chemistry Letters · 85

GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process

2015 · Michel Perron, Kirsten Stray, et al. · Antimicrobial Agents and Chemotherapy · 82

Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle

2018 · Richard L. Mackman, Victoria A. Steadman, et al. · Journal of Medicinal Chemistry · 75

Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B

2013 · Ryan C. Schoenfeld, David L. Bourdet, et al. · Journal of Medicinal Chemistry · 37

Discovery of N-[4-[6-tert-Butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B Polymerase

2013 · Francisco X. Talamas, Sarah C. Abbot, et al. · Journal of Medicinal Chemistry · 32

Works count: 6

Citation count: 441

H-index: 6

I10-index: 6